A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

NCT02718911 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: LY3022855
DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

Eli Lilly and Company

Collaborators

[object Object]